UBS Group’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

UBS Group’s Portfolio AYLA Stock Details AYLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,010	Closed	-$404	–	11482
2022 Q4	$404	Buy	+1,010	New	+$655	﹤0.01%	10204
2022 Q3	–	Sell	-2,488	Closed	-$3K	–	11492
2022 Q2	$3K	Buy	+2,488	New	+$5.68K	﹤0.01%	9461
2021 Q4	–	Sell	-431	Closed	-$5K	–	11081
2021 Q3	$5K	Sell	431 -5,078	-92%	-$60.9K	﹤0.01%	8590
2021 Q2	$56K	Buy	5,509 +4,342	+372%	+$44.6K	﹤0.01%	6333
2021 Q1	$13K	Buy	1,167 +1,074	+1,155%	+$15.3K	﹤0.01%	7763
2020 Q4	$1K	Sell	93 -324	-78%	-$3.74K	﹤0.01%	8289
2020 Q3	$5K	Buy	+417	New	+$4.88K	﹤0.01%	7360

UBS Group's AYLA Position: Q1 2023 in Review

UBS Group sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q1 2023, closing a stake of 1,010 shares — an estimated $404 sold.

UBS Group first reported a position in AYLA in Q3 2020 and held it in 7 quarters. The position peaked at $56K in Q2 2021. 0 funds tracked by Wall St. Rank hold AYLA as of Q1 2023.

UBS Group reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
UBS Group sold 1,010 Ayala Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $404.
UBS Group first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
UBS Group's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $56K in Q2 2021.
0 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.